CQDM, Healthy Brains for Healthy Lives (HBHL), Corbin Therapeutics and Brain Canada award $1.5 million to McGill Professor Philippe Gros who will pursue the development of new molecules to fight neuroinflammation

Montreal, May 2nd, 2019 – CQDM is pleased to announce that Professor Philippe Gros from McGill University has been awarded $1.5 million as part of the SynergiQC program to pursue the development and validation of new inhibitors of ubiquitin-specific protein protease (USP-15) and its partner TRIM25, that plays a key role in neuroinflammation-based disorders. From this development, Dr. Gros aims to identify a lead candidate(s) for proceeding into drug development, in view of managing and treating neuroinflammation. From this total, $655,000 will be provided by the Quebec Ministry of Economy and Innovation (MEI) through CQDM, while the balance will be funded by three partners, including $550,000 from Healthy Brains for Healthy Lives (HBHL), $279,000 from Corbin Therapeutics, and $55,000 from Brain Canada, with the financial support of Health Canada through the Canada Brain Research Fund.

Other